-
Nuvalent NASDAQ:NUVL Nuvalent, Inc. is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, Nuvalent develops innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
Location: | Website: www.nuvalent.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.009B
Cash
658M
Avg Qtr Burn
-32.61M
Short % of Float
20.87%
Insider Ownership
3.13%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NVL-520 Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Data readout | |
NVL-655 Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
NVL-330 Details HER2-expressing cancers, Cancer | Phase 1 Data readout |